Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2025 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

New drugs: improve information about uncertainties  Editorial  When new drugs enter the market, there is (sometimes great) uncertainty about their efficacy and adverse effects (1). Full article available for download (FREE) 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Inclisiran (Leqvio°) in certain types of hypercholesterolaemia  Marketing Authorisations  Inclisiran is a "small interfering" RNA intended to reduce LDL cholesterol levels in the blood. It has been authorised in the European Union for use in primary or secondary cardiovascular prevention for patients with hypercholesterolaemia, in whom statins are considered insufficiently effective or cannot be used. Does inclisiran reduce the incidence or severity of the cardiovascular complications of hypercholesterolaemia in these situations? Does it represent a therapeutic advance over alirocumab or evolocumab? And what are its adverse effects? Full article available for download by subscribers 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Abaloparatide (Eladynos°) in postmenopausal osteoporosis  Marketing Authorisations  In postmenopausal women, the main strategies for preventing fractures due to bone fragility are fall prevention and regular physical exercise. When pharmacological prevention is chosen, the first-choice option is a bisphosphonate such as alendronic acid. Abaloparatide, a parathyroid hormone agonist with a similar mechanism of action to teriparatide, has been authorised in the European Union for use in postmenopausal women with osteoporosis who are at "increased" risk of fracture. Full article available for download by subscribers 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ High cumulative doses of opioids during pregnancy: long-term neuropsychiatric harms in exposed children  Adverse Effects  When a pregnant woman experiences pain that is severe or not relieved by paracetamol, an opioid is sometimes justified. In 2024, new data were published on the long-term neurodevelopmental and neuropsychiatric harms of in-utero exposure to opioids. Full article available for download by subscribers 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Antineoplastic drugs + PPIs: shorter survival  Adverse Effects  What are the main evaluation data on the risk of excess mortality with concomitant exposure to an antineoplastic drug and a proton pump inhibitor? To what extent do these data help in making healthcare decisions? Full article available for download by subscribers 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Conflicts of interest in European health technology assessments  Advancing Healthcare Policy  Prescrire contributed to a public consultation organised by the European Commission on the procedures for managing conflicts of interest in joint health technology assessments. Full article available for download (FREE) 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ EMA: protecting personal data and commercially confidential information  Advancing Healthcare Policy  Prescrire participated in a public consultation organised by the European Medicines Agency (EMA) on the protection of personal data and commercially confidential information in marketing authorisation applications. Full article available for download (FREE) 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ EMA: assessing the risks of drugs for human reproduction and lactation  Advancing Healthcare Policy  Prescrire participated in a consultation on the revision of the "Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation". Full article available for download (FREE) 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Live attenuated cholera O1 vaccine • Relugolix + estradiol + norethisterone acetate in endometriosis • Long-term PPI treatment and gastric cancer • Antineoplastics: profits without progress > Subscribe now 1 July 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn and Facebook Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn or > Follow us on Facebook 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2025 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---